Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Bacterial Endonculease Complex Is a New Tool for Precise Mammalian Genome Engineering

By BiotechDaily International staff writers
Posted on 07 Feb 2013
A new tool based on endonucleases extracted from bacterial adaptive immune mechanisms that can be reprogrammed with customizable small, noncoding RNAs is beginning to be used to easily and specifically engineer the human genome.

Clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems provide adaptive immunity against viruses and plasmids in bacteria. The silencing of invading nucleic acids is executed by ribonucleoprotein complexes preloaded with small, interfering CRISPR RNAs (crRNAs) that act as guides for targeting and degradation of foreign nucleic acid.

The Cas9–crRNA complex of the Streptococcus thermophilus CRISPR3/Cas system introduces a double-strand break at a specific site in DNA containing a sequence complementary to crRNA. DNA cleavage is executed by Cas9, which uses two distinct active sites to generate site-specific nicks on opposite DNA strands. The Cas9–crRNA complex functions as an RNA-guided endonuclease with RNA-directed target sequence recognition and protein-mediated DNA cleavage.

The first description of genomic engineering using the CRISPR approach was published by investigators at the University of California, Berkeley (USA) in the August 17, 2012, issue of the journal Science. Two new papers by investigators at Harvard Medical School (Boston, MA, USA) appeared in the January 3, 2013, issue of Science and have established the concept of using CRISPR to modify the human and other mammalian genomes.

“Out of this somewhat obscure bacterial immune system comes a technology that has the potential to really transform the way that we work on and manipulate mammalian cells and other types of animal and plant cells,” said Dr. Jennifer Doudna, professor of molecular and cell biology and chemistry at the University of California, Berkeley. “This is a poster child for the role of basic science in making fundamental discoveries that affect human health. The ability to modify specific elements of an organism’s genes has been essential to advance our understanding of biology, including human health. However, the techniques for making these modifications in animals and humans have been a huge bottleneck in both research and the development of human therapeutics.

“Based on the feedback we have received, it is possible that this technique will completely revolutionize genome engineering in animals and plants,” said Dr. Doudna. “It is easy to program and could potentially be as powerful as the polymerase chain reaction (PCR).”

“I think this is going to be a real hit,” said Dr. George Church, professor of genetics at Harvard Medical School. “There are going to be a lot of people practicing this method because it is easier and about 100 times more compact than other techniques.”

Related Links:
University of California, Berkeley
Harvard Medical School


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.